ESMO 2023 | Novel frontline approaches to treating patients with EGFR-mutated NSCLC

Nicholas Girard, MD, PhD, Institut Curie, Paris, France, discusses the novel treatment regimens available for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Dr Girard elaborates on currenly ongoing research determining optimal sequencing of these agents in the clinic, as well as speculating on possible approaches in first line treatment failure. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.